ReviewEuropean journal of microbiology & immunology2026
Ferulic acid - A promising candidate molecule for the treatment of colitis.
Review in European journal of microbiology & immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis is an inflammatory bowel disease of multi-factorial etiology and responsible for considerable health and socioeconomic burdens given high global prevalence rates. Since current therapy options are associated with various side effects, alternative or adjunct therapy options are utmost wanted. Ferulic acid (FA) is a phenolic compound found in various plants and has attracted scientific interests due to its anti-oxidant properties and recently been hyped as a longevity compound. This systematic review summarizes current evidence for anti-colitogenic effects of FA. Results of the included studies revealed that FA, its derivatives, and synthesized FA-containing nanoparticles i.) alleviated experimental colitis; ii.) dampened pro-inflammatory immune responses; iii.) tightened the gut epithelial barrier; and iv.) reshaped the gut microbiota composition from a dysbiotic to a well-balanced "healthy" state characterized by high species diversity and dominance of probiotic bacterial taxa. Remarkably, in some studies, the observed anti-colitogenic effects of FA were even more pronounced compared to those exerted by treatment with established medications. In conclusion, FA constitutes a promising alternative or adjunct option in the treatment of ulcerative colitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.